{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:57:37Z","timestamp":1768978657003,"version":"3.49.0"},"reference-count":20,"publisher":"ALUNA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:p>Aim: to evaluate potential role of sclerostin in pathophysiology of Polycystic Ovary Syndrome, especially in relation to bone and thyroid metabolism.\nMaterials and Methods: An exploratory cross-sectional study was carried out with participation of 66 women suffering from Polycystic Ovary Syndrome and 34 healthy controls. Measurements and results obtained were for serum levels of sclerostin, osteocalcin, and thyroid-stimulating hormone by using ELISA technique.\nResults: Mean serum sclerostin levels were significantly elevated in Polycystic Ovary Syndrome group 12.5 ng\/mL\u00b14.8 compared to controls 4.8 ng\/mL\u00b12.4 with t-value having been recorded as 9.02 and P=0.000. Patients with Polycystic Ovary Syndrome showed significantly lower serum osteocalcin levels (3.7\u00b11.2 ng\/mL vs. 5.2\u00b12.2 ng\/mL, P=0.000) and higher TSH levels (6.3\u00b11.3 \u03bcIU\/mL vs. 3.4\u00b10.8 \u03bcIU\/mL, P=0.000). Pearson correlation analysis revealed a moderate negative correlation between osteocalcin and sclerostin (r=-0.458, P=0.039). ROC analysis of sclerostin exhibited a sensitivity of 79% and specificity of 62% which can be interpreted as moderate in terms of diagnostic accuracy.\nConclusions: Findings highlight that sclerostin is much raised in women with PCOS and could well be a useful biomarker of the syndrome\u2019s effects on bone and thyroid metabolism. Its moderate diagnostic performance however, further researches on its role in the pathophysiology of Polycystic Ovary Syndrome are needed.<\/jats:p>","DOI":"10.36740\/merkur202506109","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:08:49Z","timestamp":1768932529000},"page":"768","source":"Crossref","is-referenced-by-count":0,"title":["Role of sclerostin in the bone and thyroid metabolism in patients with ovarian polycystic syndrome"],"prefix":"10.36740","author":[{"given":"Zainab Tawfeeq","family":"Al-Joubouri","sequence":"first","affiliation":[{"name":"DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, FACULTY OF PHARMACY, UNIVERSITY OF KUFA, NAJAF, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaymaa Galeel","family":"Shamran","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, FACULTY OF PHARMACY, UNIVERSITY OF KUFA, NAJAF, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha Luay","family":"Aziz","sequence":"additional","affiliation":[{"name":"AL HUSSEIN TEACHING HOSPITAL, AL-MUTHANNA, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali A.","family":"Al-Fahham","sequence":"additional","affiliation":[{"name":"FACULTY OF NURSING, UNIVERSITY OF KUFA, NAJAF, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Sadeghi HM, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M, Nikfar S, Tsatsakis A, Abdollahi M. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. Int J Mol Sci. 2022;23(2):583. doi: 10.3390\/ijms23020583.","DOI":"10.3390\/ijms23020583"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Prior J, Shirin S, Goshtasebi A. Bone health and prevalent fractures in women with polycystic ovary syndrome: a meta-analysis and endocrine-context pathophysiology review. Expert Rev Endocrinol Metab. 2023;18:283-293. doi: 10.1080\/17446651.2023.2242695.","DOI":"10.1080\/17446651.2023.2216294"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today. 2015; 50(3): 117-128. doi: 10.1097\/NT.0000000000000092.","DOI":"10.1097\/NT.0000000000000092"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Premaor M, Risseti G, Piovezan J, Comim F. Contrasting bone profiles in PCOS are related to BMI: A systematic review and meta-analysis. J Endocr Soc. 2024;8:9172. doi: 10.1210\/jendso\/bvab072.","DOI":"10.1210\/jendso\/bvae163.1581"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Hristova D, Kirilov G. Hormonal status and bone turnover in adolescents with polycystic ovarian syndrome. Clin Exp Obstet Gynecol. 2022;49(2):56. doi: 10.31083\/j.ceog4902056.","DOI":"10.31083\/j.ceog4902056"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Hassan MQ, Maeda Y, Taipaleenmaki H, Zhang W, et al. miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem. 2012; 287: 42084-42092. doi: 10.1074\/jbc.M112.377515.","DOI":"10.1074\/jbc.M112.377515"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Maeda K, Kobayashi Y, Koide M, Uehara S, Okamoto M, Ishihara A, Kayama T, Saito M, Marumo K. The regulation of bone metabolism and disorders by Wnt signaling. Int J Mol Sci. 2019;20(22):5525. doi: 10.3390\/ijms20225525.","DOI":"10.3390\/ijms20225525"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Rossini M, Gatti D, Adami S. Involvement of WNT\/\u03b2-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int. 2013;93:121-132. doi: 10.1007\/s00223-013-9749-z.","DOI":"10.1007\/s00223-013-9749-z"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Walker EC, McGregor NE, Poulton IJ, Solano M, et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest. 2010; 120(2): 582-592. doi: 10.1172\/JCI40568.","DOI":"10.1172\/JCI40568"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh Y. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;14:2029-2049. doi: 10.2147\/TCRM.S138000.","DOI":"10.2147\/TCRM.S138000"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011;286:19489-19500. doi: 10.1074\/jbc.M110.190330.","DOI":"10.1074\/jbc.M110.190330"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Lin CH, Lin YC, Huang YC, Hsu CY. The association between body mass index and osteoporosis in a longitudinal cohort study of the Taiwan Biobank. Sci Rep. 2024; 14: 8509. doi: 10.1038\/s41598-024-59159-4.","DOI":"10.1038\/s41598-024-59159-4"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Bertizlio\u011flu M, Kebapcilar A, Kebapcilar L, Akyurek F, Sert Z, Celik C. Association between plasma sclerostin levels and body mass index in women with polycystic ovary syndrome. Cureus. 2023;15(9):e45152. doi: 10.7759\/cureus.45152.","DOI":"10.7759\/cureus.48875"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Wyskida K, Franik G, Owczarek A, Chor\u0119za P, et al. Plasma sclerostin levels are associated with nutritional status and insulin resistance but not hormonal disturbances in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2020;302(4):1025-1031. doi: 10.1007\/s00404-020-05656-6.","DOI":"10.1007\/s00404-020-05656-6"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Bilen O, Bilen Y, Ero\u011flu M, Turkon H, Akdeniz Y, A\u015f\u0131k M. Serum sclerostin and dickkopf-1 levels in patients with polycystic ovary syndrome. Kocatepe Med J. 2022; 23(3): 252-256. doi: 10.18229\/kocatepetip.833378.","DOI":"10.18229\/kocatepetip.833378"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Cintesun FN\u0130, Can U, Cintesun E, Altunkeser A, Kaya A, Gunenc O. Serum sclerostin level and its relation to subclinical atherosclerosis in the polycystic ovary syndrome phenotypes: A prospective controlled study. Turk J Obstet Gynecol. 2021;18(3):167-174. doi: 10.4274\/tjod.galenos.2021.51436.","DOI":"10.4274\/tjod.galenos.2021.51436"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. Mihaljevi\u0107 O, \u017divan\u010devi\u0107-Simonovi\u0107 S, Lu\u010di\u0107-Tomi\u0107 A, et al. The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction. J Med Biochem. 2020; 39: 436-443. doi: 10.5937\/jomb029835.","DOI":"10.5937\/jomb0-24943"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Rija FF, Hussein SZ, Abdalla MA. Osteoprotegerin, sclerostin, and osteocalcin serum levels in thyroid disorder patients. Ukr Biochem J. 2021;93(5):117-121. doi: 10.15407\/ubj93.05.117.","DOI":"10.15407\/ubj93.05.117"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Zygmunt A, Krawczyk-Rusiecka K, Skowro\u0144ska-Jo\u017awiak E, Wojciechowska-Durczy\u0144ska K, G\u0142owacka E, Adamczewski Z, Lewi\u0144ski A. The effect of recombinant human TSH on sclerostin and other selected bone markers in patients after total thyroidectomy for differentiated thyroid cancer. J Clin Med. 2021;10(21):4905. doi: 10.3390\/jcm10214905.","DOI":"10.3390\/jcm10214905"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20. Bjerkreim BA, Hammerstad SS, Eriksen EF. Bone turnover in relation to thyroid-stimulating hormone in hypothyroid patients on thyroid hormone substitution therapy. J Thyroid Res. 2022;2022:8950546. doi: 10.1155\/2022\/8950546.","DOI":"10.1155\/2022\/8950546"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:08:52Z","timestamp":1768932532000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2025i6net.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":20,"URL":"https:\/\/doi.org\/10.36740\/merkur202506109","relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}